MDxHealth SA (MDXH.BR) Fundamental Analysis & Valuation

EBR:MDXH • BE0974461940

Current stock price

3.02 EUR
-0.12 (-3.76%)
Last:

This MDXH.BR fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. MDXH.BR Profitability Analysis

1.1 Basic Checks

  • In the past year MDXH has reported negative net income.
MDXH.BR Yearly Net Income VS EBIT VS OCF VS FCFMDXH.BR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 -10M -20M -30M -40M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -51.61%, MDXH is doing worse than 63.64% of the companies in the same industry.
  • MDXH has a worse Return On Equity (-393.48%) than 75.32% of its industry peers.
Industry RankSector Rank
ROA -51.61%
ROE -393.48%
ROIC N/A
ROA(3y)-55.15%
ROA(5y)-64.23%
ROE(3y)-343.17%
ROE(5y)-262.12%
ROIC(3y)N/A
ROIC(5y)N/A
MDXH.BR Yearly ROA, ROE, ROICMDXH.BR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 -100 -200 -300 -400

1.3 Margins

  • The Gross Margin of MDXH (59.66%) is better than 64.94% of its industry peers.
  • MDXH's Gross Margin has declined in the last couple of years.
  • MDXH does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 59.66%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-6.79%
MDXH.BR Yearly Profit, Operating, Gross MarginsMDXH.BR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 0 -100 -200 -300

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. MDXH.BR Health Analysis

2.1 Basic Checks

  • MDXH does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for MDXH has been increased compared to 1 year ago.
  • MDXH has a worse debt/assets ratio than last year.
MDXH.BR Yearly Shares OutstandingMDXH.BR Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 5M 10M 15M
MDXH.BR Yearly Total Debt VS Total AssetsMDXH.BR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M

2.2 Solvency

  • MDXH has an Altman-Z score of -3.05. This is a bad value and indicates that MDXH is not financially healthy and even has some risk of bankruptcy.
  • MDXH's Altman-Z score of -3.05 is on the low side compared to the rest of the industry. MDXH is outperformed by 71.43% of its industry peers.
  • MDXH has a Debt/Equity ratio of 2.17. This is a high value indicating a heavy dependency on external financing.
  • The Debt to Equity ratio of MDXH (2.17) is worse than 75.32% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.17
Debt/FCF N/A
Altman-Z -3.05
ROIC/WACCN/A
WACC6.93%
MDXH.BR Yearly LT Debt VS Equity VS FCFMDXH.BR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 0 20M -20M 40M

2.3 Liquidity

  • MDXH has a Current Ratio of 2.43. This indicates that MDXH is financially healthy and has no problem in meeting its short term obligations.
  • MDXH has a Current ratio (2.43) which is comparable to the rest of the industry.
  • MDXH has a Quick Ratio of 2.27. This indicates that MDXH is financially healthy and has no problem in meeting its short term obligations.
  • MDXH has a Quick ratio (2.27) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 2.43
Quick Ratio 2.27
MDXH.BR Yearly Current Assets VS Current LiabilitesMDXH.BR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. MDXH.BR Growth Analysis

3.1 Past

  • MDXH shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -16.81%.
  • MDXH shows a strong growth in Revenue. In the last year, the Revenue has grown by 66.59%.
  • MDXH shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -1.77% yearly.
EPS 1Y (TTM)-16.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-700%
Revenue 1Y (TTM)66.59%
Revenue growth 3Y46.47%
Revenue growth 5Y-1.77%
Sales Q2Q%73.48%

3.2 Future

  • MDXH is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 51.91% yearly.
  • Based on estimates for the next years, MDXH will show a very strong growth in Revenue. The Revenue will grow by 27.69% on average per year.
EPS Next Y-6519.8%
EPS Next 2Y-619.83%
EPS Next 3Y-49.87%
EPS Next 5Y51.91%
Revenue Next Year84.81%
Revenue Next 2Y47.5%
Revenue Next 3Y43.11%
Revenue Next 5Y27.69%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
MDXH.BR Yearly Revenue VS EstimatesMDXH.BR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 20M 40M 60M 80M 100M
MDXH.BR Yearly EPS VS EstimatesMDXH.BR Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -5 -10 -15

More info and screens

Find the best growth stocksShow best growing peers

0

4. MDXH.BR Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for MDXH. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MDXH. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MDXH.BR Price Earnings VS Forward Price EarningsMDXH.BR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MDXH.BR Per share dataMDXH.BR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4

4.3 Compensation for Growth

  • A cheap valuation may be justified as MDXH's earnings are expected to decrease with -49.87% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-619.83%
EPS Next 3Y-49.87%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. MDXH.BR Dividend Analysis

5.1 Amount

  • No dividends for MDXH!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

MDXH.BR Fundamentals: All Metrics, Ratios and Statistics

MDxHealth SA

EBR:MDXH (12/15/2023, 7:00:00 PM)

3.02

-0.12 (-3.76%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A
Earnings (Next)N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap82.41M
Revenue(TTM)89.55M
Net Income(TTM)-70.04M
Analysts86.67
Price Target8.4 (178.15%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)86.3%
Min EPS beat(2)82.17%
Max EPS beat(2)90.44%
EPS beat(4)4
Avg EPS beat(4)88.67%
Min EPS beat(4)82.17%
Max EPS beat(4)98.56%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)64.31%
Min Revenue beat(2)6.24%
Max Revenue beat(2)122.37%
Revenue beat(4)4
Avg Revenue beat(4)65.41%
Min Revenue beat(4)6.24%
Max Revenue beat(4)122.37%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)814.71%
PT rev (3m)814.71%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-889.37%
EPS NY rev (3m)-731.51%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-0.5%
Revenue NY rev (3m)1.18%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.01
P/FCF N/A
P/OCF N/A
P/B 5.1
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.68
EYN/A
EPS(NY)-4.7
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS2.98
BVpS0.59
TBVpS-2.08
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -51.61%
ROE -393.48%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 59.66%
FCFM N/A
ROA(3y)-55.15%
ROA(5y)-64.23%
ROE(3y)-343.17%
ROE(5y)-262.12%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-6.79%
F-ScoreN/A
Asset Turnover0.66
Health
Industry RankSector Rank
Debt/Equity 2.17
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.43
Quick Ratio 2.27
Altman-Z -3.05
F-ScoreN/A
WACC6.93%
ROIC/WACCN/A
Cap/Depr(3y)43.52%
Cap/Depr(5y)35.7%
Cap/Sales(3y)6.07%
Cap/Sales(5y)4.71%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-16.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-700%
EPS Next Y-6519.8%
EPS Next 2Y-619.83%
EPS Next 3Y-49.87%
EPS Next 5Y51.91%
Revenue 1Y (TTM)66.59%
Revenue growth 3Y46.47%
Revenue growth 5Y-1.77%
Sales Q2Q%73.48%
Revenue Next Year84.81%
Revenue Next 2Y47.5%
Revenue Next 3Y43.11%
Revenue Next 5Y27.69%
EBIT growth 1Y-41.06%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year37.18%
EBIT Next 3Y24.82%
EBIT Next 5Y22.55%
FCF growth 1Y-63.24%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-51.31%
OCF growth 3YN/A
OCF growth 5YN/A

MDxHealth SA / MDXH.BR Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for MDxHealth SA?

ChartMill assigns a fundamental rating of 2 / 10 to MDXH.BR.


What is the valuation status of MDxHealth SA (MDXH.BR) stock?

ChartMill assigns a valuation rating of 0 / 10 to MDxHealth SA (MDXH.BR). This can be considered as Overvalued.


How profitable is MDxHealth SA (MDXH.BR) stock?

MDxHealth SA (MDXH.BR) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for MDXH stock?

The Earnings per Share (EPS) of MDxHealth SA (MDXH.BR) is expected to decline by -6519.8% in the next year.